Additionally, the CD44+CD24− cells contain a molecular signature originally identified in breast tumorigenic cells (Liu et al, 2007) that can predict patient outcome not only in breast cancer but also in prostate cancer. The gene discussed is CD44; the disease is Familial prostate cancer.